This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
Blood Cancer Journal Open Access 13 November 2015
-
Current and future treatment options for polycythemia vera
Annals of Hematology Open Access 02 April 2015
-
Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number
Blood Cancer Journal Open Access 13 April 2012
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007; 356: 459–468.
Tefferi A, Lasho TL, Schwager SM, Strand JS, Elliott M, Mesa R et al. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera. Cancer 2006; 106: 631–635.
Vannucchi AM, Pancrazzi A, Bogani C, Antonioli E, Guglielmelli P . A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia 2006; 20: 1055–1060.
Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139–4141.
Gale RE, Allen AJ, Nash MJ, Linch DC . Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years. Blood 2007; 109: 1241–1243.
Kittur J, Knudson RA, Lasho TL, Finke CM, Gangat N, Wolanskyj AP et al. Clinical Correlates of JAK2V617F Allele Burden in Essential Thrombocythemia. Cancer 2007; in press.
Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W et al. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007; 21: 270–276.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tefferi, A., Strand, J., Lasho, T. et al. Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera. Leukemia 21, 2074–2075 (2007). https://doi.org/10.1038/sj.leu.2404724
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404724
This article is cited by
-
Allelic burden of Janus kinase 2 in a 6-month course of therapy for myeloproliferative neoplasms
Molecular Biology Reports (2023)
-
JAK2V617F allele burden: innovative concept in monitoring of myeloproliferative neoplasms
memo - Magazine of European Medical Oncology (2018)
-
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors
Blood Cancer Journal (2015)
-
Current and future treatment options for polycythemia vera
Annals of Hematology (2015)
-
Clonal evolution in UKE-1 cell line leading to an increase in JAK2 copy number
Blood Cancer Journal (2012)